Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Assembly Biosciences (ASMB) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Assembly Biosciences (ASMB) over the last 10 years, with Q3 2025 value amounting to $21.7 million.

  • Assembly Biosciences' Operating Expenses rose 2174.6% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.6 million, marking a year-over-year increase of 785.8%. This contributed to the annual value of $73.9 million for FY2024, which is 296.76% up from last year.
  • Latest data reveals that Assembly Biosciences reported Operating Expenses of $21.7 million as of Q3 2025, which was up 2174.6% from $20.7 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Operating Expenses ranged from a high of $62.9 million in Q4 2021 and a low of $15.0 million during Q3 2023
  • Moreover, its 4-year median value for Operating Expenses was $19.7 million (2023), whereas its average is $23.1 million.
  • The largest annual percentage gain for Assembly Biosciences' Operating Expenses in the last 5 years was 5459.82% (2021), contrasted with its biggest fall of 3494.95% (2021).
  • Quarter analysis of 4 years shows Assembly Biosciences' Operating Expenses stood at $62.9 million in 2021, then plummeted by 68.65% to $19.7 million in 2023, then fell by 4.18% to $18.9 million in 2024, then grew by 14.73% to $21.7 million in 2025.
  • Its Operating Expenses stands at $21.7 million for Q3 2025, versus $20.7 million for Q2 2025 and $19.4 million for Q1 2025.